Insmed Q1 2024 GAAP EPS $(1.06) Beats $(1.23) Estimate, Sales $75.500M Miss $77.758M Estimate
Portfolio Pulse from Benzinga Newsdesk
Insmed (NASDAQ:INSM) reported Q1 2024 earnings with a GAAP EPS of $(1.06), surpassing the $(1.23) estimate, indicating a 13.82% beat and a 9.4% improvement from last year's $(1.17) per share. However, their sales of $75.5M fell short of the $77.758M estimate by 2.9%, despite being a 15.77% increase from the previous year's $65.214M.
May 09, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Insmed reported a better-than-expected Q1 2024 GAAP EPS of $(1.06), beating estimates by 13.82% and improving from last year's $(1.17). However, their sales of $75.5M missed estimates by 2.9%, despite a 15.77% year-over-year increase.
The positive earnings surprise with a better-than-expected EPS could provide a short-term positive sentiment among investors, offsetting the slight miss in sales expectations. The year-over-year growth in both earnings and sales demonstrates the company's improving financial health, which could support investor confidence. However, the sales miss might temper some of the positive momentum, leading to a neutral short-term impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100